GRAIL: Early Cancer Detection

Situation/Challenge

- Sponsor testing new blood test to detect cancer earlier
- Requires high volume (15,000) of adult patients with recent cancer diagnosis
- Not yet treated; cancer-free in previous 5 years
- Recruit age-stratified patients with no cancer for control group
- Consent and enroll participants to make blood donation for lab analysis
- Record outcomes yearly

Approach/Action


- Analyze EMR data, where in system patients originate
- Identify "right patient at right time," prior to surgery/treatment
- Provide staffing grant for site volume
- Relieve site burden by managing post-enrollment outcome data
- Manage sponsor to protect site personnel's time

Successful Commercial Launch

Result

- GRN's 8 sites = 6% of study sites, enrolled 3,029 (20%) subjects
- Reached enrollment goals in record time with GRN sites

Multi-Cancer Screening Study



CASE STUDY

Cancer: Immuno-oncology

Contact title(s): Director of Research and Biostatistical Studies

Potential patients touched: ~1.8m* diagnoses/year

Client since: 2016

Plan: Successful commercial launch

GRAIL: Early Cancer Detection

Situation	Determine if a new blood test can be used to detect cancer earlier than standard screening tests
	 Requires high volume (15,000) of adult patients with recent cancer diagnosis
hallenge	 Difficult to identify patients, i.e. recent cancer diagnosis, not yet treated, cancer-free in previous 5 years
	 Recruit age-stratified patients with no cancer for control group
	 Record outcomes yearly
	 Pinpoint eligible matches using proprietary tools and query data daily
Action/ Approach	 Expert clinician-verified pre-screening adds to eligibility pool
	 Via web-based enrollment/communication system, notify research coordinators of potential patient, identify appointment schedule for research approach
	 Consent and enroll participants to make blood donation for lab analysis
	 Provide staffing grant for site volume
	 Relieve site burden by managing post-enrollment outcome data
	 Manage sponsor to protect site personnel's time
Desults	

Results • GRN's 8 sites = 6% of study sites, enrolled 3,029 (20%) subjects



Reached enrollment goals in record time with GRN sites

2 ©Guardian Research Network | Confidential and Proprietary (Pharma)

PACT: Prescreening Assistance for Clinical Trials

Situation/Challenge

- Sites struggle to find patients given study difficulty and/or staff shortages
- Need to pinpoint eligible matches for multiple trials, including non-GRN studies
- Unstructured data in EMRs, notes, labs, radiology, pathology, blood bank, biomarker and genetics, specialty systems, etc.

Approach/Action

- Provide no-cost support to GRN partners
- Find eligible patients for trials conducted independently and with GRN
- Query data daily
- Deliver expert clinician-verified prescreening
- Notify coordinators via web-based portal of potential patient
- Identify appointment schedule for potential patient communication

No-cost support to GRN partners to help find eligible patients

Result

- Includes 9 studies across multiple solid tumors and hematologic malignancies
- ~ 200 patients identified for consideration, ~1,200 followed

